Annual and Biennial FDA Registration Renewals

The phrase “FDA registration renewal” can refer to different regulatory systems. A company should first identify the FDA center, establishment type, regulated activities, products, and filing platform that apply to each physical location. The same corporate group may have different renewal obligations for different facilities.

2026 Annual Renewal for Medical Device Establishments

Medical device establishments that are required to register must generally complete annual registration between October 1 and December 31. The annual process is more than confirming a company name. The owner or operator must review the establishment’s registration information and associated device listings, update inaccurate information, and complete the required electronic steps.

Foreign medical device establishments may include manufacturers, specification developers, contract manufacturers, contract sterilizers, remanufacturers, repackers, relabelers, single-use device reprocessors, and other regulated establishment types. The exact registration and listing duties depend on the operations performed and the device’s path to commercial distribution.

Establishments located in U.S. foreign trade zones may also be subject to registration and listing requirements and should accurately identify their establishment activities and location status. A foreign manufacturer should not assume that a warehouse, logistics provider, Amazon fulfillment center, or importer can substitute for the manufacturer’s own FDA obligations.

Most medical device establishments must pay the annual establishment registration fee before completing registration. For FDA fiscal year 2026, the published annual medical device establishment registration fee is $11,423. Because the annual renewal occurring in October–December 2026 is associated with the next FDA fiscal year, companies should verify the then-current fee before payment rather than relying on the prior fiscal year amount.

A consultant can assist with owner/operator account access, payment identification, facility data review, device listing verification, establishment type analysis, U.S. Agent confirmation, official correspondent information, and correction of common errors. However, registration does not mean that FDA has approved the establishment or its devices. Registration and listing are general controls and do not replace 510(k), De Novo, PMA, IDE, quality system, labeling, Medical Device Reporting, Unique Device Identification, or other requirements that may apply.

2026 Annual Renewal for Prescription and OTC Drug Establishments

Domestic and foreign establishments that manufacture, prepare, propagate, compound, or process drugs for U.S. commercial distribution may be required to register with FDA and list their commercially marketed drug products. Covered activities can include manufacturing, repacking, relabeling, and certain testing or control operations. Drug establishment registration must generally be renewed annually between October 1 and December 31.

The annual drug renewal applies to establishments associated with prescription drugs and nonprescription, or OTC, drugs. Common OTC product categories include sunscreens, antiperspirants, fluoride toothpastes, dandruff shampoos, acne treatments, certain antiseptic products, and some hand sanitizers. Whether a particular product is lawfully marketed depends on more than registration. The product must also comply with applicable drug listing, labeling, active ingredient, dosage form, monograph, approved application, manufacturing, and quality requirements.

Drug establishment registration and drug listing data are submitted electronically, generally using Structured Product Labeling files through FDA’s Electronic Submissions Gateway or an approved submission method. Foreign companies often need specialized assistance because small inconsistencies can prevent successful processing. Examples include an FEI mismatch, an outdated D‑U‑N‑S Number record, an incorrect labeler code relationship, a legal name that does not match FDA records, missing business operation codes, obsolete U.S. Agent information, or a drug listing that no longer reflects the marketed label.

Drug companies should also avoid confusing annual establishment renewal with annual product reporting, NDC listing updates, establishment inspection obligations, or user-fee programs. Each requirement has its own legal basis. A registration consultant should clearly explain which services are included and which regulatory filings require separate work.

2026 Biennial Renewal for Food and Dietary Supplement Facilities

Section 415 of the Federal Food, Drug, and Cosmetic Act requires covered domestic and foreign facilities that manufacture, process, pack, or hold food for consumption in the United States to register with FDA. These food facility registrations must be renewed during the period beginning October 1 and ending December 31 of each even-numbered year. Therefore, the 2026 biennial renewal period is expected to run from October 1 through December 31, 2026.

The requirement applies to covered facilities handling human food and animal food. Dietary supplements are legally regulated as a category of food, so facilities manufacturing, processing, packing, or holding dietary supplements may need to maintain food facility registration. The exact analysis depends on the facility’s activities and any available exemption.

FDA has stated that a food facility registration that is not renewed by the deadline will be considered expired. A shipment from a facility with an expired, canceled, or otherwise invalid registration may face delays or refusal-related issues because registration information is used in import screening and Prior Notice review.

A food renewal is also an opportunity to correct ownership information, facility trade names, emergency contact details, product categories, activity types, U.S. Agent information, parent company details, and other required data. Companies should not wait until the final days of December to discover that they have lost access to the FDA Industry Systems account or registration PIN.

There is no FDA government fee for ordinary food facility registration or biennial renewal. Professional consultants charge service fees for regulatory review, data preparation, account assistance, submission, U.S. Agent service, document retention, confirmation, and post-renewal support. Clients should distinguish a consultant’s professional fee from an FDA government fee.

Food Canning Establishments and Scheduled Process Filings

Manufacturers of acidified foods and low-acid canned foods may have additional obligations beyond ordinary food facility registration. A Food Canning Establishment may need to submit Form FDA 2541 and file scheduled processes for each applicable product, container, formulation, and processing method using the appropriate forms or electronic filing system.

It is important not to describe the FCE system as if it were simply another biennial food registration. Food facility registration and FCE/process filing are separate compliance systems. A canning establishment that is required to register as a food facility must still complete the 2026 food facility biennial renewal. It must also keep its FCE information and scheduled processes accurate and submit updates or new process filings when required.

A foreign canning facility should review changes in processing equipment, retort systems, thermal processes, formulations, container dimensions, product styles, critical factors, operating procedures, and process authority documentation. A change that appears commercially minor can be significant from a scheduled process perspective.

Cosmetic Facility Registration Renewals Under MoCRA

MoCRA created mandatory facility registration and cosmetic product listing obligations for many cosmetic manufacturers, processors, and responsible persons. A covered cosmetic facility must renew its registration every two years. FDA’s current instructions explain that the renewal date is generally based on the date of initial facility registration. For example, a facility initially registered on February 20, 2024 would generally have a renewal due by February 20, 2026.

This differs from food facility registration, which uses a fixed October 1–December 31 renewal period in every even-numbered year. It also differs from drug establishment registration, which follows an annual October–December cycle. A company manufacturing both cosmetics and OTC drugs may therefore have two distinct regulatory systems and two distinct renewal obligations.

Examples of dual-status products include certain anti-dandruff shampoos, fluoride toothpastes, antiperspirants, acne products, and sunscreens. These products may be cosmetics because they cleanse, beautify, or alter appearance, and drugs because they are intended to treat, mitigate, prevent, or affect the structure or function of the body. Dual-status products must comply with both applicable cosmetic and drug requirements.

MoCRA also requires annual updates to cosmetic product listings. Facility registration renewal should not be confused with product listing maintenance. Companies should review responsible person information, product categories, brand names, manufacturing facilities, ingredient information, discontinued products, and contact details.

A qualified U.S. FDA consultant can help a foreign cosmetic business determine whether a small-business exemption may apply, whether a location is a manufacturer or processor, whether a contract facility must register, and whether products are cosmetics, drugs, or both. Classification should be completed before renewal because the wrong registration path can create false assurance.

The U.S. Agent Requirement for Foreign Establishments

Foreign establishments in several FDA-regulated sectors must designate a U.S. Agent. The agent’s legal role varies by program, but the central purpose is to provide FDA with a reliable U.S.-based communication point for the foreign facility.

Foreign food facilities must designate a U.S. Agent who lives or maintains a place of business in the United States and is physically present in the United States. The agent acts as the communication link between FDA and the facility. For food registration, FDA may require confirmation that the agent has agreed to serve.

Foreign medical device establishments must identify one U.S. Agent as part of establishment registration. The same person may also be designated as Official Correspondent, but that is not required. The U.S. Agent assists FDA communications, may help schedule inspections, and receives information or documents from FDA on behalf of the foreign establishment.

Foreign drug establishments, including certain manufacturers, repackers, relabelers, control laboratories, API manufacturers, and establishments involved with human or veterinary drugs or biological products, may also need a U.S. Agent. Accurate agent information is essential because FDA communications can involve registration questions, inspection planning, import concerns, listing issues, safety matters, or enforcement correspondence.

Annual or biennial renewal is an excellent time to change a U.S. Agent because the establishment is already reviewing its registration record. Nevertheless, a company generally should not wait until renewal if the existing agent has resigned, is unresponsive, has incorrect contact information, or is no longer authorized. Changes should be submitted promptly under the applicable program.

Why Companies Use U.S. FDA Consultants for 2026 Renewals

FDA electronic systems are designed for regulatory submissions, not necessarily for convenience. Foreign companies may face language barriers, time-zone differences, unfamiliar legal terminology, inaccessible legacy accounts, incorrect facility identifiers, and uncertainty about which establishment type applies. A consultant can organize the renewal as a controlled compliance project rather than a last-minute online transaction.

D‑U‑N‑S Numbers, FEI Numbers, and Registration Numbers

Foreign exporters often use the terms D‑U‑N‑S Number, FEI Number, registration number, owner/operator number, and FCE Number as if they were interchangeable. They are not.

A D‑U‑N‑S Number is a location-specific business identifier issued by Dun & Bradstreet. FDA currently recognizes it as the acceptable Unique Facility Identifier for food facility registration. The D‑U‑N‑S record should match the facility’s legal name and physical address.

An FDA Establishment Identifier, or FEI, is an identifier used by FDA for facilities in its inventory. FEIs are widely used in drug, device, biologics, inspection, and import-related records. An FEI does not by itself prove that every required registration or listing is active.

A food facility registration number is issued through the food registration system. A medical device establishment also has registration-related identifiers, but completion of annual registration and fee payment is what maintains the active status. A drug establishment’s current status should be confirmed through applicable registration records and DECRS.

When a registration has expired or been canceled, simply requesting a “new number” is not always the correct first step. FDA records should be reviewed to determine whether the facility should renew, reactivate, update, create a new registration, or correct an identifier mismatch. Creating duplicate records can make future compliance more difficult.

Consequences of Missing a 2026 Renewal

Failure to renew can produce regulatory and commercial consequences. FDA may consider a food facility registration expired. A medical device establishment may no longer appear as currently registered, and its device listings may not be properly maintained. A drug establishment may be omitted from current registration records. An expired cosmetic facility registration can create MoCRA compliance concerns.

At the border, invalid or inconsistent data can affect automated screening. Importers, customs brokers, Amazon, distributors, pharmacies, retailers, and commercial partners may also request evidence that the foreign establishment is properly registered. Even when a shipment is not immediately refused, a missing renewal can delay onboarding, vendor approval, insurance review, financing, or marketplace verification.

Registration does not cure substantive violations. A facility may have an active registration and still face action for adulteration, misbranding, unapproved drugs, unauthorized medical devices, inadequate current good manufacturing practice, missing FSVP documentation, incorrect labeling, unfiled scheduled processes, or failure to report adverse events. Renewal should therefore be integrated into a broader compliance review.

FDA enforcement tools vary by product and legal authority and can include import detention, refusal of admission, warning letters, registration suspension in certain food cases, seizure, injunction, civil money penalties where authorized, mandatory recall authorities, or criminal enforcement. The practical goal is not merely to keep a number active, but to maintain a facility and product portfolio that can withstand regulatory scrutiny.

2026 Renewal Preparation Checklist

Companies should begin collecting this information before October 2026. Waiting until the last week of December creates avoidable risk, especially when a U.S. Agent must confirm the appointment, a D‑U‑N‑S record must be corrected, an FDA account must be recovered, or an establishment fee payment must clear.

Frequently Asked Questions

Make 2026 Renewal a Compliance Review, Not a Deadline Crisis

The 2026 FDA registration cycle will affect a wide range of foreign manufacturers and exporters. Medical device and drug establishments face annual renewal obligations. Food and dietary supplement facilities face the biennial food facility renewal period because 2026 is an even-numbered year. Cosmetic manufacturers and processors must track their own MoCRA biennial renewal dates. Acidified and low-acid canned food manufacturers must review separate FCE and scheduled process obligations.

The most effective renewal strategy begins with accurate classification. A company must know what it manufactures, which FDA center regulates each product, what activities occur at each physical location, which registration systems apply, and whether the products require additional listings, filings, approvals, notifications, or quality controls.

Foreign facilities should also confirm their U.S. Agent, D‑U‑N‑S Number, FEI, ownership records, importer relationships, FDA account access, and product listings. These details are not clerical trivia. They are part of the regulatory identity used by FDA, importers, brokers, customers, and marketplaces.

A U.S. FDA consultant can coordinate the process, identify inconsistencies, prepare the renewal, communicate with the facility, maintain submission evidence, and provide continued U.S. Agent support. The best time to begin is before the renewal portal becomes crowded and before a shipment, purchase order, or marketplace account depends on an active record.